Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes

Dahai Jiang, Hungyen Lee & William M. Pardridge

Niemann-Pick C1 (NPC1) is a lysosomal cholesterol storage disorder, that severely affects the brain, and is caused by mutations in the NPC1 gene, which encodes an intracellular membrane transporter of non-esterified cholesterol. Therapeutic options for NPC1 are few, and classical enzyme replacement therapy with the recombinant protein is not possible as the NPC1 gene product is an insoluble membrane protein, which increases the need for development of gene therapy for NPC1. While viral based gene therapy is under development, it is important to investigate alternative approaches to brain gene therapy without viral vectors. The present work develops a plasmid DNA approach to gene therapy of NPC1 using Trojan horse liposomes (THLs), wherein the plasmid DNA is encapsulated in 100 nm pegylated liposomes, which are targeted to organs with a monoclonal antibody against the mouse transferrin receptor. THLs were encapsulated with a 8.0 kb plasmid DNA encoding the 3.9 kb human NPC1 open reading frame, under the influence of a 1.5 kb platelet derived growth factor B (PDGFB) promoter. THLs were administered weekly beginning at 6–7 weeks in the NPC1−/− null mouse, and delivery of the plasmid DNA, and NPC1 mRNA expression in brain, spleen, and liver were confirmed by quantitative PCR. THL treatment reduced tissue inclusion bodies in brain, and peripheral organs, but did not prolong lifespan in these mice. The work suggests that early treatment after birth may be required to reverse this disease model with NPC1 gene replacement therapy.

Niemann-Pick C1 (NPC1) disease is an inherited lysosomal storage disorder caused by mutations in the gene encoding the NPC1 protein, which is a 200 kDa intracellular membrane transporter of non-esterified cholesterol. Cell cholesterol accumulation leads to intracellular inclusion bodies, which cause neurodegeneration, and hepatosplenomegaly. The disease causes early mortality in most cases, and is associated with dementia, seizures, ataxia, and decreased audition. There is no approved therapy for NPC1. New treatments may be tested in the NPC1 null mouse (NPC1−/−), such as the NPC1m1N mouse, and the systemic administration of large doses of hydroxypropyl beta cyclodextrin (HPβCD) to NPC1−/− mice prolongs lifespan. HPβCD does not cross the blood–brain barrier (BBB), and HPβCD administration to NPC1 patients uses intrathecal administration via injections into the lumbar cerebrospinal fluid (CSF). However, intrathecal drug delivery to brain only allows for drug exposure at the CSF surface of the brain, and intrathecal HPβCD has not been approved. NPC1 gene therapy with adeno-associated virus (AAV) serotypes, e.g. AAV9, is possible, particularly with self-complementary AAV (scAAV), as these serotypes cross the BBB. However, the maximal size of the expression cassette that can be inserted in the scAAV is < 2.3 kb, and the size of the NPC1 open reading frame alone is 3.9 kb. Single stranded AAV (ssAAV) traverses the BBB less efficiently, but this viral genome will accept expression cassettes as large as 4.7 kb.

An alternative approach to NPC1 gene therapy is the use of Trojan horse liposomes (THLs). THLs are formed by encapsulation of non-viral plasmid DNA in the interior of 100–150 nm pegylated liposomes, which are targeted with a receptor-specific monoclonal antibody (MAb). The MAb targets a receptor expressed on the BBB, such as the transferrin receptor (TIR). The TIRMAB is conjugated on the surface of the THL and acts as a molecular Trojan horse to ferry the liposome-encapsulated plasmid DNA across both the BBB and the brain cell plasma membrane, followed by delivery of the plasmid DNA to the nuclear compartment. Plasmid DNAs as large as 22 kb can be encapsulated in THLs, and genes encoded in such large plasmid DNAs are expressed...
in vivo in the brain following IV administration of THLs\textsuperscript{14}. Therefore, a large therapeutic gene such as NPC1 can be placed under the influence of a large promoter that is specific for neurons. One such neuron-selective promoter is 1.5 kb of the 5′-flanking sequence of the human platelet derived growth factor-B (PDGFB) gene\textsuperscript{15}. The PDGFB promoter enables high transgene expression in the brain in vivo\textsuperscript{16,17}, and produces a higher degree of transgene expression in neurons as compared to the cytomegalovirus (CMV) promoter\textsuperscript{18}.

In the present investigation, 6 week old NPC1\textsuperscript{m1N} mice were treated with weekly IV administration of either vehicle or TfRMAb targeted THLs encapsulating a 8 kb expression plasmid DNA encoding the 1.5 kb PDGFB promoter and the 3.9 kb human NPC1 open reading frame. The IV injection dose was 6 μg plasmid DNA per mouse, which was shown by quantitative PCR to deliver multiple copies of the plasmid DNA per brain cell.

Results

Bioactivity of pPDGFB-NPC1 plasmid DNA, recombinant TfRMAb, and THL stability at 4 °C. Lipofection of COS cells with the pPDGFB-NPC1 plasmid DNA resulted in a level of expression of the 180–200 kDa NPC1 protein comparable to the expression produced with the pCMV-NPC1 plasmid DNA (Fig. 1). A faint 200 kDa band is observed in the control cells and may represent endogenous COS cell NPC1. The bioactivity of the THL binding to the mouse TfR was confirmed by ELISA using the mouse TfR1 extra-cellular domain (ECD) as the capture agent (Fig. 2). The ED50 of binding of the unconjugated TfRMAb was 0.35 ± 0.10 nM and the binding of the TfRMAb conjugated to DSPE-PEG2000 via the thio-ether linkage had an ED50 of 2.0 ± 0.7 nM (Fig. 2). The TfRMAb targeted THL encapsulating the pGL4 luciferase expression plasmid produced high levels of luciferase gene expression following the application of freshly prepared THLs to mouse 3T3 cells (Table 1). Conversely, if the TfRMAb was replaced by rat IgG, then no luciferase gene expression was
of the study in the vehicle and THL groups, respectively. The male mice had a BW of 23 ± 2 g and 23 ± 1 g at the
multi-lamellated. The vacuoles in brain were visibly reduced on the H&E stain in the THL treated mice (Fig. 3B),
(Fig. 4C,D) showed multiple vacuolations in the cytoplasm of brain cells and these vacuoles were frequently
73 ± 5 days, respectively, following treatment with vehicle or THLs, and the male mice were euthanized at 75 ± 2
and mice were dosed a total of 5 consecutive weeks until the mice were so ill that euthanasia was necessary. There
TfRMAb targeted THLs encapsulating the pPDGFB-NPC1 plasmid was started when the mice were 44 days old,
< 0.001). P
weight was 37% and 33% in the female and male groups, respectively (Table 2). When the spleen and liver weights were normalized by BW for each mouse, the increase in spleen
was no difference in survival between the treatment groups, and the female mice were euthanized at 77 ± 1 and
there was no statistical change in brain
was no difference in body weight (BW) between the
treatment groups at the end of the study (Table 2). There was a significant 10% increase in liver weight in the male mice treated with THLs
and mice were euthanized at 44 ± 2 days following treatment with vehicle or THLs, and the male mice were euthanized at 75 ± 2
and 37% increase in spleen weight in the THL group as compared to the vehicle group in the females and males,
Whitney exact 2-tailed test.

**NPC1<sup>−/−</sup> mouse treatment study.** Weekly IV treatment of the NPC1<sup>m1N</sup> mice with either vehicle or
TfRMAb targeted THLs encapsulating the pPDGFB-NPC1 plasmid was started when the mice were 44 days old,
and mice were dosed a total of 5 consecutive weeks until the mice were so ill that euthanasia was necessary. There
was no difference in survival between the treatment groups, and the female mice were euthanized at 77 ± 1 and
73 ± 5 days, respectively, following treatment with vehicle or THLs, and the male mice were euthanized at 75 ± 2
and 75 ± 3 days, respectively, following treatment with vehicle or THLs. At euthanasia, all mice demonstrated
tremors, ruffled fur, yellow coat, and abnormal gait. There was no difference in body weight (BW) between the
treatment groups at the end of the study (Table 2). The female mice had a BW of 17 ± 2 g and 18 ± 2 g at the start
of the study in the vehicle group and THL groups, respectively. There was no statistical change in brain
weight was 37% and 33% in the female and male groups, respectively (P < 0.001).

Brain hematoxylin and eosin (H&E) stains showed visible vacuolation of brain cells in the vehicle treated mice
with no sex differences and a representative scan is shown in Fig. 3A, where an arrow marks a site of vacuolation.
Electron microscopy of the terminal brain of the NPC1<sup>−/−</sup> mouse, treated with either vehicle (Fig. 4A,B) or THLs
(Fig. 4C,D) showed multiple vacuolations in the cytoplasm of brain cells and these vacuoles were frequently
multi-lamellated. The vacuoles in brain were visibly reduced on the H&E stain in the THL treated mice (Fig. 3B),
and no vacuolation was observed in brain of control mice (Fig. 3C). Glial fibrillary acidic protein (GFAP) immuno-
histochemistry showed extensive astrogliosis in the thalamus of the vehicle treated mice (Fig. 5A), and this
astrogliosis was reduced in the THL treated mice (Fig. 5B), with minimal astrogliosis in the same region of the
control mouse (Fig. 5C). The percent area of each section immune stained for GFAP was 12.9 ± 1.4% and 6.7 ± 0.8
(mean ± SD, N = 10 mice per group) for the vehicle and THL groups of mice, respectively (P < 0.0001). The
astrogliosis in the cerebellum was even greater than that shown for the thalamus, and the cerebellar astrogliosis was
not reduced by THL treatment (data not shown). H&E stains of the spleens of the vehicle treated mice showed
extensive vacuolation of spleen cells (arrow, Fig. 3D) with no sex differences, and this vacuolation was reduced in the
THL treated mice (Fig. 3E), with no vacuolation visible in the spleen of control mice (Fig. 3F). H&E stains of the
livers of the vehicle treated mice showed extensive vacuolation of hepatic cells (arrow, Fig. 3G) with no
sex differences, and this vacuolation was reduced in the THL treated mice (Fig. 3H), with no vacuolation visible in
liver cells of control mice (Fig. 3I).

Quantitative PCR on organs removed 4 days following the last dose of vehicle or THLs showed high lev-
els of pPDGFB-NPC1 plasmid DNA in target organs, and the plasmid abundance had a tissue rank order of
spleen > liver > brain in the THL treated group (Table 3). The RT-PCR measurements of NPC1 mRNA in these

| TTHL storage at 4 °C (days) | TfRMAb/pGL4 THLs | Rat IgG/pGL4 THLs |
|-----------------------------|------------------|------------------|
|                             | 24 h             | 48 h             | 24 h             | 48 h             |
| 0                           | 55 ± 3           | 92 ± 9           | < 1              | < 1              |
| 1                           | 66 ± 2           | 108 ± 7          | < 1              | < 1              |
| 5                           | 62 ± 6           | 119 ± 2          | < 1              | < 1              |

**Table 1.** Luciferase expression (pg/mg protein) in mouse 3T3 fibroblasts at 24 or 48 h after application of
THLs encapsulating the pGL4 luciferase expression plasmid DNA and targeted with either the TfRMAb or the
isotype rat IgG. Prior to application to the 3T3 cells, the THLs were stored at 4 °C for 0, 1, or 5 days. Data are
mean ± SD (3 dishes per time point).

| Sex     | Treatment | Spleen       | Liver         | Brain        | Body weight |
|---------|-----------|--------------|---------------|--------------|-------------|
| Female  | Vehicle   | 74 ± 18      | 969 ± 129     | 340 ± 39     | 13.3 ± 1.3  |
| Male    | Vehicle   | 86 ± 15      | 1,100 ± 102   | 360 ± 39     | 16.9 ± 1.0  |
| Female  | THL       | 105 ± 17<sup>a</sup> | 994 ± 80   | 360 ± 19     | 13.9 ± 1.1  |
| Male    | THL       | 118 ± 14<sup>a</sup> | 1,211 ± 100<sup>ab</sup> | 361 ± 28     | 17.5 ± 0.6  |

**Table 2.** Terminal organ weights (mg wet tissue) and body weights (grams) in female and male NPC1<sup>−/−</sup> mice
treated with either vehicle or THLs. Mean ± SD (N = 8 female or 10 male mice per vehicle or THL treatment
group). *P < 0.005 by unpaired 2-tailed T test; †P < 0.0001 by unpaired 2-tailed T test; ‡P < 0.05 by Mann
Whitney exact 2-tailed test.
Figure 3. H&E stains of cerebral cortex (A–C), spleen (D–F), and liver (G–I) from NPC1+/− mice or control mice at euthanasia. Panels (A, D, G) are NPC1+/− mice treated with vehicle; panels (B, E, H) are NPC−/− mice treated with TIRMAb/pPDGFB-NPC1 THLs. Panels (C, F, I) are control mice. Arrows in panels (A, D, G) point to cholesterol-laden cells in brain, spleen, and liver, respectively. Brain sections are through cortical layers I–IV. Magnification is the same for all panels and the panel A magnification bar = 100 microns.

Figure 4. Electron microscopy of cerebral cortex of vehicle (A, B) or THL (C, D) treated NPC1−/− mouse at euthanasia. Multi-lamellated vacuoles of varying size are present in the cytoplasm of brain cells. Magnification in panels (A) and (C) is the same and magnification bar in panel (A) is 1,000 nm; magnification in panels (B) and D is the same and magnification bar in panel (B) is 1,000 nm.
Figure 5. GFAP immunocytochemistry of thalamus of NPC1−/− mouse treated with vehicle (A) or the TfRMAb/pPDGF-NPC1 THLs (B). The GFAP immunocytochemistry of thalamus from a control mouse is shown in (C). Sections are counter-stained with hematoxylin. Magnification of all 3 panels is the same and the panel (A) magnification bar = 100 microns.

Table 3. Organ concentrations (pg plasmid DNA per mg wet tissue) in female and male NPC1−/− mice at 4 days following the last IV injection of either vehicle or THLs. Mean ± SEM (N = 4 male or 4 female mice per vehicle or THL treatment group). PCR Cq values were converted to pg plasmid DNA with a pPDGF-NPC1 plasmid DNA standard curve.
Chronic treatment of the NPC1−/− mice with THLs increased tissue NPC1 mRNA levels, as compared to vehicle treated mice. THL treatment caused an increase in the NPC1-GAPDH ΔCq values in a pattern, spleen > liver ≈ brain (Table 4), which paralleled the organ concentrations of the pPDGFB-NPC1 plasmid DNA (Table 3). The ΔΔCq values between THL and vehicle treatment groups showed the NPC1 mRNA, relative to the GAPDH mRNA, was increased 8,192-fold, 338-fold, and 238-fold in spleen, brain, and liver, respectively. NPC1 Western blot of spleen extracts showed detectable 200 kDa NPC1 protein in the THL treated mice, with no visible NPC1 protein in the vehicle treated mice (Fig. 6). The NPC1 protein paralleled the NPC1 mRNA, as immunoreactive NPC1 protein could not be detected with Western blot of extracts of brain or liver in the THL treated mice.

Chronic treatment of the NPC1−/− mice with THLs caused the formation of a low titer anti-drug antibody (ADA) response against the TfRMAb protein. The OD/μL was 0.16 ± 0.08, in the vehicle treated group with no sex differences, whereas the OD/μL was 1.57 ± 0.02 in the THL treated group with no sex differences. These ADA titers are low compared to a significant ADA response, which can produce ADA titers >> 100 OD/μL.19.

Discussion

This investigation attempts to treat the NPC1m1N null mouse with intravenous plasmid DNA therapy using THLs that target the mouse TfR1, and an expression plasmid DNA, designated pPDGFB-NPC1, encoding the 3.9 kb human NPC1 open reading frame driven by a 1.5 kb promoter taken from the human PDGFB 5′-flanking sequence. Weekly IV injections of THLs or vehicle was administered to a cohort of 36 NPC1−/− mice starting at the age of 44 days (6–7 weeks) at a dose of 6 μg plasmid DNA per mouse. The findings of this study are consistent with the following conclusions. First, weekly IV administration of THLs produces high levels of the pPDGFB-NPC1 plasmid DNA in the target organs (brain, spleen, liver) as shown by quantitative PCR (Table 3), and that the plasmid is transcribed to produce tissue levels of the NPC1 mRNA in proportion to the tissue plasmid DNA level (Tables 3, 4). Second, chronic THL administration produces visible reductions in the vacuolation of cells in liver and spleen (Fig. 3), which correlates with increases in weights of these organs, particularly the spleen (Table 2). This finding parallels the observations of other studies of the NPC1−/− mouse, which showed the spleen weight is increased in the untreated NPC1−/−, relative to control mice, and that spleen weights are increased further by therapy20. Third, chronic THL administration produces visible reductions in the vacuolation of cells in liver and spleen (Fig. 3), which correlates with increases in weights of these organs, particularly the spleen (Table 2). This finding parallels the observations of other studies of the NPC1−/− mouse, which showed the spleen weight is increased in the untreated NPC1−/−, relative to control mice, and that spleen weights are increased further by therapy20. Third, chronic THL administration produces visible reductions in the vacuolation of cells in the cerebral cortex (Fig. 3A,B), which correlates with a significant reduction in astrogliosis, based on quantitation of GFAP immunocytochemistry (“Results” section and Fig. 5). Fourth, initiation of THL therapy at 6–7 weeks of age is too late to reverse the severe clinical effects of congenital NPC1 absence, and THL therapy caused no change in the decline in body weight or early death at 10–11 weeks (“Results” section).

The NPC1−/− mouse replicates many of the findings of human NPC1, including cholesterol storage disease in brain, spleen, and liver, neurodegeneration associated with astrogliosis and severe vacuolation of brain cells.23.
The disease in the NPC1−/− mouse is eliminated by insertion of the 3.9 kb murine NPC1 cDNA under the influence of a 3.6 kb prion promoter21. Therefore, gene therapy offers a promising approach to the treatment of NPC1, which currently has no FDA approved therapy. The standard approach to gene therapy of the brain is the use of adeno-associated virus (AAV), and certain AAV serotypes, such as AAV9, cross the BBB following IV administration8. The use of ssAAV, which has twice the cloning capacity of scAAV9, and the development of mini-promoters, allows for the insertion of a large therapeutic gene such as the 3.9 kb NPC1 open reading frame into the AAV genome22,23,24. The NPC1 gene with a 227 nucleotide elongation factor-1α (EF1α) promoter was delivered to NPC1−/− mouse brain with AAV9 following IV administration of high injection doses (ID), 1–2 × 1014 vg/kg of the virus22. Treatment caused an increase in lifespan from 69 ± 3 days to 166 ± 89 days, and 20–30% of brain cells were transduced in the regions studied, layer V of the cortex and the CA3 region of the hippocampus22. In a second study of treatment of the NPC1−/− mouse with the NPC1 gene encoded in AAV9 under the influence of the CMV promoter, the virus was administered by injection into the left cardiac ventricle at a high ID of 1 × 1014 vg/kg in 4 day old mice, which resulted in a modest increase in lifespan from 71 ± 4 days to 94 ± 4 day23. In a third study, a low dose, 5 × 1012 vg/kg, or a high dose, 2 × 1014 vg/kg, of AAV9 carrying the NPC1 gene, under the influence of the human synapsin 1 promoter, was administered into both lateral ventricles of a newborn mouse24. This bilateral intra-cerebroventricular (ICV) route of administration of the AAV9 bypassed the BBB. The low ID produced an increase in lifespan no greater than that produced by daily oral high dose (1,200 mg/kg/day) miglustat, whereas the high ID increased lifespan to an average of 158 days24. The longer lifespan after bilateral ICV injection of high doses of AAV9 is attributed to the greater distribution of the AAV9 within the brain following a bilateral ICV injection in the newborn mouse. Prior work shows widespread gene distribution in the brain following ICV administration in the newborn mouse25, which is attributed to the shorter diffusion distances in the small brain of a mouse, particularly the brain of a 1 g newborn mouse. No matter the route of administration, the effect of NPC1 gene therapy in the NPC1−/− mouse requires a high ID of 1014 vg/kg22,23,24. However, this ID of 1014 vg/kg of AAV may be genotoxic, as a 1014 vg/kg dose of AAV administered as a single injection in newborn mice produces a 70% incidence of hepatic carcinoma in mice observed for up to 21 months26. AAV-induced liver cancer was dependent on the promoter/enhancer used in the vector design26, and liver cancer has not been observed in humans. Nevertheless, the theoretical concerns of AAV genotoxicity provides the rationale for parallel examination of plasmid DNA-based gene therapy. Plasmid DNA gene therapy requires a DNA drug delivery system, and the THL delivery technology was developed for this purpose21.

Plasmid DNA as large as 22 kb has been successfully encapsulated in THLs, followed by expression in brain after IV administration18. Therefore, there was no restriction on the size of the promoter that could be used in the engineering of a NPC1 expression plasmid. The 1.5 kb human PDGFB promoter18 was used, which produced a 6.0 kb expression cassette, and a 8.0 kb plasmid DNA (“Methods” section). The PDGFB promoter is expressed in neurons, and produces a greater level of transgene expression in brain, as compared to the CMV promoter. The pPDGFB-NPC1 plasmid DNA was delivered to brain, spleen, and liver with intravenous THLs, and the tissue plasmid DNA concentrations at 4 days following the last IV dose of the study are shown in Table 3. The brain plasmid DNA concentration is 10 pg DNA per mg tissue (Table 3), which corresponds to 1.1 × 106 DNA molecules per mg brain tissue, based on the molecular weight of a 8.0 kb double stranded plasmid DNA of 5.3 × 106 g/mole. There are 100 million cells per 400 mg mouse brain27, or 0.25 × 106 cells/mg brain. These calculations indicate there are 4–5 plasmid DNA molecules delivered per each cell in brain of the mouse with the THL delivery system, which correlates with prior estimates of THL delivery of plasmid DNA to brain cells in the primates28. There is an even greater number of plasmid DNA molecules delivered to spleen and liver cells, with spleen > liver (Table 3). The greater uptake of THLs by spleen as compared to liver is attributed to the much higher expression of the TIR1 isoform in spleen as compared to liver29, as it is the TIR1 isoform that is targeted by the TIRMAb used in this study.

The lack of a therapeutic effect on survival in the NPC1−/− mouse, when therapy is not initiated until 6–7 weeks, suggests disease stage at the start of therapy determines the therapeutic outcome, as described previously for other lysosomal storage disorders that affect the brain30. The severe accumulation in brain of autophagic lysosomal inclusion bodies, such as those found at termination in this study (Fig. 4), are present in the brain of the NPC1−/− mouse as early as 6 weeks of age, or when therapy was initiated in this study32. The astrogliosis observed in this study (Fig. 5), as well as microglial activation, begins in brain of the NPC1−/− mouse as early as 2 weeks of age30,24. Suppression of myelin production begins as early as 5 weeks of age31.

In conclusion, this investigation shows that the NPC1 plasmid DNA can be delivered to target organs of the NPC1 mouse with intravenous administration of THLs that target the TIR, but that therapy must be initiated much earlier than 6–7 weeks of age in the NPC−/− mouse. Since TIRMAb targeted THLs cross the placenta, plasmid DNA therapy of the NPC1−/− mouse could even begin in utero.

**Methods**

**Plasmid DNA.** A luciferase expression plasmid, pGL4.13, and designated pGL4, was purchased from Promega (Madison, WI). A human NPC1 expression plasmid (#SC120010), under the influence of the CMV promoter, is designated pCMV-NPC1, and was purchased from Origene (Rockville, MD). A human NPC1 mouse with intravenous administration of THLs that target the TIR, but that therapy must be initiated much earlier than 6–7 weeks of age in the NPC−/− mouse. Since TIRMAb targeted THLs cross the placenta, plasmid DNA therapy of the NPC1−/− mouse could even begin in utero.
expression plasmid, under the influence of the human PDGF-B promoter, was custom synthesized as a 5.6 kb expression cassette, which was subcloned in a 8.0 kb pUC plasmid DNA at Genscript (Piscataway, NJ), and the sequence of the entire expression cassette was confirmed by bidirectional DNA sequencing. The NPC1 open reading frame corresponded to nucleotides 164–4,000 of NM_000271, and was preceded on the 5′ end by a 9 nucleotide (nt) Kozak sequence, and a 1.5 kb human PDGF-B promoter, and on the 3′ end by the bovine growth hormone (BGH) poly A sequence, which corresponded to nt 2,974–3,198 of MK988448. The sequence of the PDGF-B promoter corresponds to nt = 1,360 to + 75, relative to the transcription start site15. The transcription start site was identified by Blast alignment of the human PDGF-B mRNA, NM_002608, and the human PDGF-B gene, NG_002599. The PDGFB-NPC1-BGH expression cassette was confirmed by bidirectional DNA sequencing, and encoded for the human NPC1 protein corresponding to amino acids (AA) 1–1,278 of the human NPC1 protein sequence, NP_000262. Transfection grade (low endotoxin) gigapreps of all plasmids were prepared, and plasmid constructs were confirmed by restriction endonuclease digestion and agarose gel electrophoresis.

Production of recombinant TFRMAb. THL delivery to the mouse brain targets the mouse TfR type 1 with the 8D3 rat MAb against the mouse TfR, which was previously produced from hybridoma generated ascites39. The AA sequences of the variable region of the heavy chain, VH, and the variable region of the light chain, VL, of this antibody has been described previously30. A recombinant form of the 8D3 TFRMAb was produced following the engineering of separate heavy chain (HC) and light chain (LC) expression cassettes. The HC expression plasmid encoded for the 118 AA 8D3 VH followed by the 322 AA rat IgG2a constant region, and the LC expression plasmid encoded for the 108 AA 8D3 VL and the 106 AA rat kappa B allele constant region. HC and LC synthetic genes were produced at Genscript (Piscataway, NJ), and subcloned, with a signal peptide in a eukaryotic expression plasmid with a CMV promoter and a human growth hormone polyA sequence. The expression plasmids were confirmed by bidirectional DNA sequencing. Chinese hamster ovary (CHO) K1 cells were dual electroporated, followed by propagation of the cells in serum free medium in a 14 day fed batch culture, and the TFRMAb was affinity purified with protein G to yield 3 g of recombinant TFRMAb. The purity, identity, and potency of the TFRMAb was confirmed by reducing and non-reducing sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), size exclusion HPLC, mouse IgG Western blotting, and a TfR binding ELISA with the mouse TfR1 ECD (VWR, Radnor, PA). The endotoxin content of the TFRMAb was low, <0.5 EU/mg, as determined with the Limulus amebocyte lysate (LAL) spectrophotometric assay (ThermoFisher Scientific, Waltham, MA).

Lipofection and NPC1 Western blotting. COS cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA), and grown in Eagle medium with 10% fetal bovine serum. Cells were plated in 6-well dishes and lipofected with 2 μg/dish of either pCMV-NPC1 or pPDGFB-NPC1 and Lipofectamine 2000 (ThermoFisher, Carlsbad, CA). After 2 days of transfection, washed monolayers were lysed and separated in 6-well dishes and lipofected with 2 μg/dish of either pCMV-NPC1 or pPDGFB-NPC1 and Lipofectamine Collection (ATCC, Manassas, VA), and grown in Eagle medium with 10% fetal bovine serum. Cells were plated with 6 mol% to the phospholipid to enable storage of the THLs at 4°C for several days prior to administration to NPC1 found to reduce the number of DNA-free or empty liposomes to < 10% of total. Second, cholesterol was added at amount of phospholipid used to encapsulate 400 μg DNA was reduced fourfold from 40 to 10 μmol, as this was found to reduce the number of DNA-free or empty liposomes to < 10% of total. Second, cholesterol was added at 6 mol% to the phospholipid to enable storage of the THLs at 4°C for several days prior to administration to NPC1 mice. This level of cholesterol stabilizes membranes38. Third, the plasmid DNA encapsulation in the liposomes is enhanced with the addition of ethanol40. A 10 μmol mixture of phospholipid [8.7 μmol POPC, 0.6 μmol cholesterol, 0.3 μmol DDAB, 0.3 μmol DSPE-PEG2000 0.1 μmol DSPE-PEG2000-maleimide (MAL)] dissolved in chloroform was evaporated to a thin film, and phospholipids were hydrated by vortexing and brief bath sonication in 400 μL of 0.05 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffered water (HBW, pH = 7.0), followed by the addition of 400 μg plasmid DNA in Tris–EDTA (TE) buffer. An equal volume of 80% ethanol was added. Following a series of freeze/thaw cycles, the phospholipid/DNA mix was extruded several times through an LF-1 extruder (Avestin, Ottawa, Canada) with a 200 nm polycarbonate filter. As the ethanol inhibits nuclease activity40, the ethanol was removed by dialysis using a Slide-A-Lyzer with a 20 kDa MW cut-off (ThermoFisher). The THL prep were produced in duplicate, which were pooled prior to dialysis, and non-encapsulated plasmid DNA was removed by treatment with bovine pancreatic DNase I (Sigma, St. Louis, MO) and Ecoli exonuclease II (ThermoFisher)12. Prior to conjugation of the TFRMAb to the maleimide (MAL) moieties on the surface of the liposome, the MAb (2.5 mg) was thiolated with a 15:1 molar ratio of 2-iminothiolane (Sigma), which produced 2–3 thiol groups per MAb, based on the reaction with Ellman’s reagent (Sigma). The unconjugated MAb and the nuclease digested DNA was removed by Sepharose CL-4B gel filtration chromatography in 0.05 M Hepes buffer (pH = 7.0)14, and the THL peak in the void volume was pooled and micro-filtered with a 0.2 micron Millex GF filter unit (Millipore-Sigma), and stored at 4°C until either analysis or overnight shipping on cold packs to The Jackson Laboratory (JAX, Bar Harbor, ME). The typical THL prep had DNA concentration of 40 μg/mL, a TFRMAb concentration of 100 μg/mL, and a phospholipid concentration of 1.5 mg/mL. Approximately...
40–50 TIRMab molecules were conjugated to each liposome, and the number of non-encapsulated or “empty” liposomes was <10%. The diameter of the THL was 100–150 nm as determined by a dynamic light scattering particle analyzer (Nicomp model N3000, Entegris, Billerica, MA). Following agarose gel electrophoresis and ethidium bromide staining, all of the plasmid DNA was trapped at the top of the gel, which indicates the DNA is fully encapsulated. Following solubilization of the THLs with 0.2% Triton X-100, the plasmid DNA entered the gel and showed the same migration as the untreated super-coiled DNA. The retention of the plasmid DNA in the interior of the THL was confirmed with the QuantiFluor dsDNA System (Promega) using a Quantus fluorometer (Promega). The endotoxin content was measured with the LAL assay and was 0.06–0.12 endotoxin units (EU)/mL.

**TfRMAb ELISA.** The conjugation of the TfRMAb to the THL results in the formation of DSPE-PEG<sub>2000</sub>-S-TfRMAb within the intact THL, where the -S- represents the thioether bond conjugating the TfRMAb to the maleimide (MAL) moiety at the tip of the PEG<sub>2000</sub> group on the surface of the THL. This lipid-PEG<sub>2000</sub>-S-MAb unit is released from the THL following solubilization with 0.2% Triton X-100. The binding of the THL-PFG2000-TfRMAb to the mouse TIR1 ECD was compared to the unconjugated TIRMab with an ELISA, where the capture agent was the mouse TIR1 ECD, and the detector reagent was a conjugate of alkaline phosphatase and a goat anti-rat kappa light chain antibody (Millipore-Sigma) with measurement of colorimetric absorption (Abs) at 405 nm. Binding of either the unconjugated TIRMab, or the THL-TFMR-PEG was measured between 3 and 3,000 ng/mL using an iMark microplate absorbance reader (BioRad). Rat IgG alone produced no ELISA signal. The concentration of antibody that produces 50% of maximal binding, ED50, was determined by non-linear regression by fitting the data to: Abs = (Amax·S)/(EC50 + S), where Amax is the maximal Abs and S = the concentration of TIRMab. The EC50 was estimated with the units of ng/mL, and converted to units of nM, based on a MAb MW of 150,000 Da. The same MW was used for either the unconjugated TIRMab or the DSPE-PEG<sub>2000</sub>-MAL-TIRMab, because the amount of the latter added to the ELISA wells was based on protein content as determined with the bicinchoninic acid (BCA) protein assay (ThermoFisher).

**Luciferase gene expression.** The stability of the THLs with storage at 4 °C was determined by encapsulation of the pG4 luciferase expression plasmid DNA in TIRMab targeted THLs. The THLs were stored at 4°C for up to 5 days prior to application (2 μg plasmid DNA per 35 mm dish) to cultured mouse 3T3 fibroblasts (ATCC), and intracellular luciferase enzyme activity was determined with the Bright-Glo Luciferase assay (Promega) and a Glo-Max 20/20 luminometer (Promega). The relative light units (RLU) were converted to pg luciferase with a standard curve using recombinant firefly luciferase (Promega), and the data normalized per mg protein in the well based on the BCA assay.

**Npc1<sup>−/−</sup> mouse treatment study.** A colony of 36 Npc1<sup>−/−</sup> mice, also called the NPC1<sup>inm</sup> mouse (16 females, 20 males), was developed at The Jackson Lab (JAX, Bar Harbor, ME) for this study (JAX stock #003092). The study protocol was approved by the JAX Institutional Animal Care and Use Committee, and all experiments were performed in accordance with relevant guidelines and regulations. Genotype of all mice was confirmed by tail PCR. The mice were divided into 2 treatment groups of 18 mice (8 females, 10 males), with the first group treated by vehicle (Hepes buffer, pH = 7.0), and the second group treated with TfRMAb-targeted THLs encapsulating the pPDGFB-NPC1 plasmid DNA (designated TLC-200). Each mouse was treated by weekly tail vein injections of a volume of 150 μL. The injection dose (ID) in the THL treated mice was 6 μg plasmid DNA per mouse, and the ID of the TIRMab was 15 μg per mouse. THLs were not frozen prior to injection, and it was necessary for JAX to perform sterility testing on each batch. THLs were shipped on cold packs on Monday of the week following the last weekly dose and on Tuesday, with sterility results available on Friday, or 4 days following THL production. Weekly IV treatment began at 44 days (6–7 weeks) of age. Mice were monitored weekly with body weights and clinical signs (tremor, ruffled fur, yellow coat, abnormal gait). At euthanasia, brain, liver, and spleen were removed from all mice for organ weights. The organs were then divided in two parts, with the first part flash frozen on dry ice, and shipped to the sponsor overnight on dry ice. The second part was placed in cold 4% paraformaldehyde and shipped on cold packs overnight to the sponsor.

**Organ histology.** The fixed tissues were embedded in paraffin for 5 micron sections followed by either H&E staining or GFAP immunohistochemistry at the UCLA Tissue Pathology Core Lab. Sections were performed on brains from 20 mice (10 from each treatment group), and on liver and spleen from 12 mice (6 from each treatment group). Digital images at 20X magnification were obtained for all magnifications with an Aperio Image system (Leica Biosystems, Buffalo Grove, IL). The GFAP immune staining was quantified as percent area with NIH Image J (version 1.52a) for the thalamus of the vehicle and THL treated Npc1<sup>−/−</sup> mice. Sections were quantified for 10 mice (5 male, 5 female) for the vehicle treated group, and for 10 mice (5 male, 5 female) for the THL treated group, and 3 fields per section were averaged. Statistical differences between the vehicle and THL treated mice were assessed with the unpaired Student's t test. Transmission electron microscopy was performed on brains from 2 vehicle treated mice and 2 THL treated mice. The brain in paraformaldehyde fixative was enriched to 2% glutaraldehyde, treated with 1% OsO<sub>4</sub> and embedded in epon. Ultra-thin (50 nm) sections on 200 mesh copper grids were stained with uranyl acetate and lead citrate and examined at 60 kV with a JEOL JEM-100CX II electron microscope at the UCLA Brain Research Institute core laboratory. Photographs were taken with an AMT XR611 camera at 2.5 s exposure.

**Quantitative PCR and RT-PCR.** The mice were euthanized at 4 days following the last weekly dose of vehicle or THL. The frozen brain, liver, and spleen (40 mg) was homogenized and plasmid DNA isolated with

https://doi.org/10.1038/s41598-020-70290-w
a QIAprep Spin Miniprep kit (Qiagen, Valencia, CA). The pPDGFB-NPC1 plasmid DNA per mg wet tissue weight was quantified by real time PCR using a CFX Connect Real-Time PCR Detect System (BioRad, Hercules, CA), specific PCR primers, and a standard curve with serial dilutions (1.7 × 10^5 to 1.7 × 10^6) plasmid copy number (PCN) per μl of the pPDGFB-NPC1 plasmid DNA. The Cq (earliest cycle of fluorescence detection) varied from 8.2 at 10^4 PCN/μl to 29.3 at 10^6 PCN/μl, and the Cq was > 36 when no plasmid DNA was added to the mix. The forward and reverse PCR primers were designed at the IDT Real Time qPCR Assay Entry website based on a sequence of the human NPC1 mRNA (NM_000271) with mismatches to the mouse NPC1 mRNA (AF003348). The forward (sense) primer sequence is 5′-CTGCGCTGCTGTCTGATC-3′ and the reverse (antisense) primer sequence is 5′-AAATCCGGCAAGAGAGAAG-3′, which produces an amplicon length of 103 nucleotides, a Tm of 62 °C, and a GC content of 48–50%. PCR was performed with the PowerUp SYBR Green Master Mix (ThermoFisher) and 40 cycles of denaturation (95°C, 15 s) and annealing (51.3°C, 30 s). The Cq (earliest cycle of fluorescence detection) was determined for both the pPDGFB-NPC1 plasmid standard and the tissue samples, and tissue Cq was converted to pg pPDGFB-NPC1 plasmid based on the standard curve.

NPC1 mRNA was measured for brain, liver, and spleen by reverse transcriptase (RT)-PCR. The tissue Cq value for NPC1 was compared to the Cq value for a housekeeping gene, glyceraldehyde 3′-phosphate dehydrogenase (GAPDH). Although GAPDH transcripts may vary among tissues14, there was no difference in organ Cq values for GAPDH between the vehicle and THL treated mice (Table 4). The mouse GAPDH primers were derived from the mouse GAPDH mRNA sequence (XM_017321385). The forward (sense) primer sequence is 5′-GGG TGTGAAACACGAGAAATA-3′ and the reverse (antisense) primer sequence is 5′-GTCATGAACCTCCTTCCACA AT-3′, which produces an amplicon length of 129 nucleotides, a Tm of 62°C, and a GC content of 48–50%. Organ RNA was isolated from homogenates with the RNeasy Mini Kit (Qiagen), and the RNA was quantified with the QuantiFluor RNA System (Promega). cDNA was produced from the RNA with the iScript Reverse Transcription Supermix (Biorad) and cDNA was used twice, each sample was measured in triplicate in each assay. PCR was performed with both the mouse NPC1 and the mouse GAPDH primers. The ΔCq is the difference in Cq value for NPC1 and GAPDH for a given organ. The ΔΔCq is the difference in ΔCq for the vehicle treated mouse and the THL treated mouse. The change in NPC1 mRNA abundance in the organ of the THL treated mouse was computed from the base 2 antilog of the ΔΔCq using the Omni antilog calculator.

**Anti-drug antibody ELISA.** The anti-drug antibody (ADA) response against the TIRMB following chronic treatment of NPC1−/− mice with either vehicle or THLs was measured on the terminal serum by ELISA. The capture agent for the ADA ELISA is the recombinant TIRMB, and the detector agent in the ELISA is a complex of biotinylated TIRMBs and a conjugate of streptavidin and horseradish peroxidase (Vector Labs), and color development, at 490 nm, was measured with the ortho-phenylenediamine chromagen. The TfRMAb complex of biotinylated TfRMAb and a conjugate of streptavidin and horseradish peroxidase (Vector Labs), was biotinylated with sulfo-NHS-LC-LC-biotin (ThermoFisher), where NHS = N-hydroxysuccinimide, and 4-hydroxybenzotriazole was added to the mix. The biotinylation of the TfRMAb was confirmed by Western blotting with the ABC vectastain reagent (Vector Labs). The ADA titer was reported as the optical density (OD) per μL mouse serum19.

Received: 2 March 2020; Accepted: 27 July 2020
Published online: 07 August 2020

**References**

1. Burlina, A. Niemann-Pick disease type C: introduction and main clinical features. *J. Neurol.* **261**(Suppl 2), S525–S527. https://doi.org/10.1007/s00415-014-7382-z (2014).
2. Pentchev, P. G. et al. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. *Biochim. Biophys. Acta* **619**, 669–679. https://doi.org/10.1016/0005-2760(80)90116-2 (1980).
3. Loftus, S. K. et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. *Science* **277**, 232–235. https://doi.org/10.1126/science.277.5323.232 (1997).
4. Ramírez, C. M. et al. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. *Pediatr. Res.* **68**, 309–315. https://doi.org/10.1002/ptr.2801e3181ee4dd2 (2010).
5. Pontikis, C. C., Davidson, C. D., Walkley, S. U., Platt, F. M. & Begley, D. J. Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability. *J. Inherit. Metab. Dis.* **36**, 491–498. https://doi.org/10.1007/s10545-012-9583-x (2013).
6. Ory, D. S. et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial. *Lancet* **390**, 1758–1768. https://doi.org/10.1016/S0140-6736(17)31465-4 (2017).
7. Pardridge, W. M. CSF, blood-brain barrier, and brain drug delivery. *Expert. Opin. Drug. Deliv.* **13**, 963–975. https://doi.org/10.1517/17425247.2016.1171315 (2016).
8. Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. *Nat. Biotechnol.* **27**, 59–65. https://doi.org/10.1038/nbt.1515 (2009).
9. Hudry, E. et al. Efficient gene transfer to the central nervous system by single-stranded Anc80L65. *Mol. Ther. Methods Clin. Dev.* **10**, 197–202. https://doi.org/10.1016/j.omtm.2018.07.006 (2018).
10. Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. *Mol. Ther.* **19**, 1058–1069. https://doi.org/10.1038/mt.2011.72 (2011).
11. Pardridge, W. M. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. *Cold Spring Harb. Protoc.* https://doi.org/10.1101/pdb.prot5407 (2010).
12. Zhang, Y., Jeong Lee, H., Boado, R. J. & Pardridge, W. M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. *J. Gene Med.* **4**, 183–194. https://doi.org/10.1002/jgm.255 (2002).
13. Zhang, Y., Schlauchetti, F. & Pardridge, W. M. Global non-viral gene transfer to the primate brain following intravenous administration. *Mol. Ther.* **7**, 11–18. https://doi.org/10.1002/sctm.1525-0016/000018-7 (2003).
14. Xia, C. F. et al. Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes. *J. Gene Med.* **9**, 605–612. https://doi.org/10.1002/jgm.1046 (2007).
15. Sasahara, M. et al. PDGF-B chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. *Cell* **64**, 217–227. https://doi.org/10.1016/0092-8674(91)90223-1 (1991).
The authors are indebted to The Jackson Laboratory (Bar Harbor, ME) for maintenance of the NPC1−/− mouse colony and the weekly intravenous injections. The work was supported by NIH/NINDS Grant R44NS098877.

Acknowledgements

The authors are indebted to The Jackson Laboratory (Bar Harbor, ME) for maintenance of the NPC1−/− mouse colony and the weekly intravenous injections. The work was supported by NIH/NINDS Grant R44NS098877.

Author contributions

D.J. and H.L. executed the experiments; W.M.P. designed the study, and wrote the manuscript, and all authors edited the manuscript.

Competing interests

D.J., H.L., and W.M.P. were employees of The Lipogene Company, Inc.

Additional information

Correspondence and requests for materials should be addressed to W.M.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
